董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Kush M. Parmar | 男 | Director | 39 | 未披露 | 未持股 | 2020-05-31 |
| Vicki Sato | 女 | Director | 71 | 未披露 | 未持股 | 2020-05-31 |
| Arthur O. Tzianabos | 男 | Director | 57 | 4.20万美元 | 未持股 | 2020-05-31 |
| Emmanuel Simons | 男 | President and Chief Executive Officer, Director | 37 | 77.17万美元 | 未持股 | 2020-05-31 |
| Kush M. Parmar | -- | Director | 39 | 未披露 | 未持股 | 2020-05-31 |
| Chris Smith | 男 | Director | 57 | 5.70万美元 | 未持股 | 2020-05-31 |
| Saira Ramasastry | 女 | Director | 44 | 未披露 | 未持股 | 2020-05-31 |
| Heather Preston | 女 | Director | 54 | 未披露 | 未持股 | 2020-05-31 |
| Edward T. Mathers | 男 | Director | 60 | 未披露 | 未持股 | 2020-05-31 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Gregory Robinson | 男 | Chief Scientific Officer | 61 | 39.74万美元 | 未持股 | 2020-05-31 |
| Emmanuel Simons | 男 | President and Chief Executive Officer, Director | 37 | 77.17万美元 | 未持股 | 2020-05-31 |
| Michael McKenna | 男 | Chief Medical Officer | 63 | 53.83万美元 | 未持股 | 2020-05-31 |
| Rabia Gurses Ozden | 女 | Chief Development Officer | 52 | 未披露 | 未持股 | 2020-05-31 |
董事简历
中英对照 | 中文 | 英文- Kush M. Parmar
-
Kush M. Parmar ，从2013年7月起担任Vor Biopharma Inc.董事会成员。他目前担任5AM Ventures（风险资本公司）的一般合伙人，从2010年6月起在5AM Ventures工作。此前，他是Harvard 医学院一家健康医师科学家研究所的院士，在Massachusetts General & Brigham和omen’s Hospitals 完成了临床见习；为肿瘤初创企业提供咨询服务。他还在数个私有企业董事会任职。他还是 Society of Kauffman Fellows的一位院士。持有Princeton 大学学士学位，Harvard 大学博士学位和Harvard 医学院医学博士学位。
Kush M. Parmar has served as our co-chief executive officer and as a member of our board of directors since our inception in August 2020. Dr. Parmar is also Managing Partner at 5AM and joined in 2010 from Harvard Medical School, where he was an NIH-sponsored M.D./Ph.D. Physician Scientist Fellow in the Harvard-MIT Health Sciences and Technology Program. Dr. Parmar serves or has served as a director on the boards of Akouos, Inc. Nasdaq: AKUS, Arvinas, Inc. (Nasdaq: ARVN), Audentes Therapeutics, Inc. (which was acquired by Astellas Pharma Inc.), Entrada Therapeutics, Inc., Homology Medicines, Inc. (Nasdaq: FIXX), Rallybio Holdings, LLC, scPharmaceuticals, Inc (Nasdaq: SCPH), Vor Biopharma Inc. (Nasdaq: VOR), and Ensoma Inc. He previously served as Acting VP of Strategy and Corporate Development at Novira Therapeutics, Inc. (which was acquired by Johnson & Johnson) and served as board observer for Envoy Therapeutics Inc. (which was acquired by Takeda Pharmaceutical Company Limited), Achaogen, Inc. (Nasdaq: AKAO) and Pulmatrix, Inc. (Nasdaq: PULM). Dr. Parmar serves on the advisory boards of Harvard Medical School, Penn Medicine, Princeton University's Department of Molecular Biology, and the Grace Science Foundation. He is a Fellow of the Society of Kauffman Fellows. Before joining 5AM, Dr. Parmar completed clinical clerkships at the Massachusetts General & Brigham and Women's Hospitals. He holds an A.B. in Molecular Biology and Medieval Studies from Princeton University, a Ph.D. in Experimental Pathology from Harvard University and an M.D. from Harvard Medical School. - Kush M. Parmar ，从2013年7月起担任Vor Biopharma Inc.董事会成员。他目前担任5AM Ventures（风险资本公司）的一般合伙人，从2010年6月起在5AM Ventures工作。此前，他是Harvard 医学院一家健康医师科学家研究所的院士，在Massachusetts General & Brigham和omen’s Hospitals 完成了临床见习；为肿瘤初创企业提供咨询服务。他还在数个私有企业董事会任职。他还是 Society of Kauffman Fellows的一位院士。持有Princeton 大学学士学位，Harvard 大学博士学位和Harvard 医学院医学博士学位。
- Kush M. Parmar has served as our co-chief executive officer and as a member of our board of directors since our inception in August 2020. Dr. Parmar is also Managing Partner at 5AM and joined in 2010 from Harvard Medical School, where he was an NIH-sponsored M.D./Ph.D. Physician Scientist Fellow in the Harvard-MIT Health Sciences and Technology Program. Dr. Parmar serves or has served as a director on the boards of Akouos, Inc. Nasdaq: AKUS, Arvinas, Inc. (Nasdaq: ARVN), Audentes Therapeutics, Inc. (which was acquired by Astellas Pharma Inc.), Entrada Therapeutics, Inc., Homology Medicines, Inc. (Nasdaq: FIXX), Rallybio Holdings, LLC, scPharmaceuticals, Inc (Nasdaq: SCPH), Vor Biopharma Inc. (Nasdaq: VOR), and Ensoma Inc. He previously served as Acting VP of Strategy and Corporate Development at Novira Therapeutics, Inc. (which was acquired by Johnson & Johnson) and served as board observer for Envoy Therapeutics Inc. (which was acquired by Takeda Pharmaceutical Company Limited), Achaogen, Inc. (Nasdaq: AKAO) and Pulmatrix, Inc. (Nasdaq: PULM). Dr. Parmar serves on the advisory boards of Harvard Medical School, Penn Medicine, Princeton University's Department of Molecular Biology, and the Grace Science Foundation. He is a Fellow of the Society of Kauffman Fellows. Before joining 5AM, Dr. Parmar completed clinical clerkships at the Massachusetts General & Brigham and Women's Hospitals. He holds an A.B. in Molecular Biology and Medieval Studies from Princeton University, a Ph.D. in Experimental Pathology from Harvard University and an M.D. from Harvard Medical School.
- Vicki Sato
-
Vicki Sato自2020年2月以来一直担任我们的董事会成员。她于2006年9月至2017年7月担任哈佛商学院管理实践教授，并于2005年7月至2015年10月担任哈佛大学分子和细胞生物系教授。从2000年到2005年，她曾担任Vertex Pharmaceuticals公司（生物技术公司）的总裁。从1994年到2000年，她是Vertex研究与开发的高级副总裁，从1992年到1994年，她是研究的Vice President和首席科学官。在加入Vertex之前，佐藤博士曾担任BiogenInc.研究Vice President。佐藤博士自2006年起担任百时美施贵宝公司董事，自2014年起担任博格华纳公司董事，自2015年4月起担任Denali Therapeutics，Inc.董事，自2016年12月起担任VirBiotechnology，Inc.董事。佐藤博士曾于2013年8月至2019年12月担任SyrosPharmaceuticals，Inc.董事会成员。佐藤博士在Radcliffe College获得生物学学士学位，在Harvard University获得生物学硕士和博士学位。她在加州大学伯克利分校（University of California，Berkeley）和斯坦福医学中心（Stanford Medical Center）进行博士后工作。
Vicki Sato has served on our board of directors since February 2020. She was a professor of management practice at Harvard Business School from September 2006 to July 2017 and was a professor in the Department of Molecular and Cell Biology at Harvard University from July 2005 until October 2015. From 2000 to 2005 she served as president of Vertex Pharmaceuticals, Inc., a biotechnology company. From 1994 to 2000 she was the senior vice president of research and development at Vertex and from 1992 to 1994 she was the vice president of research and chief scientific officer. Prior to joining Vertex, Dr. Sato served as vice president of research at Biogen Inc. Dr. Sato has served on the board of directors at Bristol Myers Squibb Company since 2006 BorgWarner, Inc. since 2014 Denali Therapeutics, Inc. since April 2015 and Vir Biotechnology, Inc. since December 2016. Dr. Sato previously served on the board of Syros Pharmaceuticals, Inc. from August 2013 to December 2019. Dr. Sato received her A.B. in Biology from Radcliffe College and her A.M. and Ph.D. in Biology from Harvard University. She conducted her postdoctoral work at both the University of California, Berkeley and Stanford Medical Center. - Vicki Sato自2020年2月以来一直担任我们的董事会成员。她于2006年9月至2017年7月担任哈佛商学院管理实践教授，并于2005年7月至2015年10月担任哈佛大学分子和细胞生物系教授。从2000年到2005年，她曾担任Vertex Pharmaceuticals公司（生物技术公司）的总裁。从1994年到2000年，她是Vertex研究与开发的高级副总裁，从1992年到1994年，她是研究的Vice President和首席科学官。在加入Vertex之前，佐藤博士曾担任BiogenInc.研究Vice President。佐藤博士自2006年起担任百时美施贵宝公司董事，自2014年起担任博格华纳公司董事，自2015年4月起担任Denali Therapeutics，Inc.董事，自2016年12月起担任VirBiotechnology，Inc.董事。佐藤博士曾于2013年8月至2019年12月担任SyrosPharmaceuticals，Inc.董事会成员。佐藤博士在Radcliffe College获得生物学学士学位，在Harvard University获得生物学硕士和博士学位。她在加州大学伯克利分校（University of California，Berkeley）和斯坦福医学中心（Stanford Medical Center）进行博士后工作。
- Vicki Sato has served on our board of directors since February 2020. She was a professor of management practice at Harvard Business School from September 2006 to July 2017 and was a professor in the Department of Molecular and Cell Biology at Harvard University from July 2005 until October 2015. From 2000 to 2005 she served as president of Vertex Pharmaceuticals, Inc., a biotechnology company. From 1994 to 2000 she was the senior vice president of research and development at Vertex and from 1992 to 1994 she was the vice president of research and chief scientific officer. Prior to joining Vertex, Dr. Sato served as vice president of research at Biogen Inc. Dr. Sato has served on the board of directors at Bristol Myers Squibb Company since 2006 BorgWarner, Inc. since 2014 Denali Therapeutics, Inc. since April 2015 and Vir Biotechnology, Inc. since December 2016. Dr. Sato previously served on the board of Syros Pharmaceuticals, Inc. from August 2013 to December 2019. Dr. Sato received her A.B. in Biology from Radcliffe College and her A.M. and Ph.D. in Biology from Harvard University. She conducted her postdoctoral work at both the University of California, Berkeley and Stanford Medical Center.
- Arthur O. Tzianabos
-
ArthurO.Tzianabos博士自2016年4月起担任我们的总裁，首席执行官兼董事会成员。Tzianabos博士从Ovascience，Inc.加入Homology，Ovascience，Inc.是一家生物技术公司，此后与MillendoTherapeutics，Inc.合并，他于2013年9月至2016年3月担任总裁兼首席科学官。任职Ovascience公司之前，Tzianabos博士曾在Shire plc（一家生物技术公司）任职8年，在那里他担任越来越重要的职务，包括发现研究、Vice President、项目管理和高级副总裁高级主管以及研究和早期开发主管。Tzianabos从1992年到2005年担任Harvard Medical School教员，在Channing Laboratory，Brigham and Women&8217；s Hospital以及Harvard Medical School微生物和分子遗传学系维护实验室。Tzianabos博士目前担任StokeTherapeutics，Inc.的董事Tzianabos博士曾担任BindTherapeutics，Inc.公司的董事。Tzianabos博士拥有波士顿学院（Boston College）生物学学士学位和新罕布什尔大学（University of New Hampshire）微生物学博士学位。
Arthur O. Tzianabos,spent eight years at Shire plc, a biotechnology company, where he served in positions of increasing responsibility, including Senior Director, Discovery Research, Vice President, Program Management and Senior Vice President and Head, Research and Early Development. From 1992 to 2005, Dr. Tzianabos was a faculty member at Harvard Medical School and maintained laboratories at the Channing Laboratory, Brigham and Women's Hospital and the Department of Microbiology and Molecular Genetics at Harvard Medical School. Dr. Tzianabos has served as chairman and a director of Stoke Therapeutics, Inc. (NASDAQ: STOK), a public biotechnology company, since April 2018. Dr. Tzianabos previously served as chairman of the board of directors of Akouos, Inc., a public biotechnology company, from July 2018 until its acquisition by Eli Lilly in December 2022, and a director of BIND Therapeutics, Inc., a biotechnology company, from October 2015 until its acquisition by Pfizer in July 2016. Dr. Tzianabos holds a B.S. in Biology from Boston College and a Ph.D. in Microbiology from the University of New Hampshire, and completed a Post-Doctoral Fellowship in Immunology at Harvard Medical School. - ArthurO.Tzianabos博士自2016年4月起担任我们的总裁，首席执行官兼董事会成员。Tzianabos博士从Ovascience，Inc.加入Homology，Ovascience，Inc.是一家生物技术公司，此后与MillendoTherapeutics，Inc.合并，他于2013年9月至2016年3月担任总裁兼首席科学官。任职Ovascience公司之前，Tzianabos博士曾在Shire plc（一家生物技术公司）任职8年，在那里他担任越来越重要的职务，包括发现研究、Vice President、项目管理和高级副总裁高级主管以及研究和早期开发主管。Tzianabos从1992年到2005年担任Harvard Medical School教员，在Channing Laboratory，Brigham and Women&8217；s Hospital以及Harvard Medical School微生物和分子遗传学系维护实验室。Tzianabos博士目前担任StokeTherapeutics，Inc.的董事Tzianabos博士曾担任BindTherapeutics，Inc.公司的董事。Tzianabos博士拥有波士顿学院（Boston College）生物学学士学位和新罕布什尔大学（University of New Hampshire）微生物学博士学位。
- Arthur O. Tzianabos,spent eight years at Shire plc, a biotechnology company, where he served in positions of increasing responsibility, including Senior Director, Discovery Research, Vice President, Program Management and Senior Vice President and Head, Research and Early Development. From 1992 to 2005, Dr. Tzianabos was a faculty member at Harvard Medical School and maintained laboratories at the Channing Laboratory, Brigham and Women's Hospital and the Department of Microbiology and Molecular Genetics at Harvard Medical School. Dr. Tzianabos has served as chairman and a director of Stoke Therapeutics, Inc. (NASDAQ: STOK), a public biotechnology company, since April 2018. Dr. Tzianabos previously served as chairman of the board of directors of Akouos, Inc., a public biotechnology company, from July 2018 until its acquisition by Eli Lilly in December 2022, and a director of BIND Therapeutics, Inc., a biotechnology company, from October 2015 until its acquisition by Pfizer in July 2016. Dr. Tzianabos holds a B.S. in Biology from Boston College and a Ph.D. in Microbiology from the University of New Hampshire, and completed a Post-Doctoral Fellowship in Immunology at Harvard Medical School.
- Emmanuel Simons
-
Emmanuel Simons于2016年3月共同创立了Akouos，自成立以来一直担任我们的总裁兼首席执行官，并担任我们的董事会成员。在创立Akouos之前，Simons博士于2014年11月至2016年8月在生物技术公司VoyagerTherapeutics，Inc.担任商业和企业发展领导职务，并于2012年6月至2014年11月在生物技术公司Warp Drive Bio LLC担任领导职务。在他的职业生涯早期，西蒙斯博士是旗舰创业公司（Flagship Pioneural）的一名企业家，也是赛里斯治疗公司创始团队的成员之一Simons博士在哈佛学院（Harvard College）以优异成绩获得神经科学和音乐学士学位，在麻省理工学院（Massachusetts Institute of Technology）获得生物医学工程博士学位，在哈佛商学院（Harvard Business School）获得工商管理硕士学位。
Emmanuel Simons co-founded Akouos in March 2016 and has served as our president and chief executive officer and as a member of our board of directors since our inception. Prior to founding Akouos, Dr. Simons held leadership roles in business and corporate development at Voyager Therapeutics, Inc., a biotechnology company, from November 2014 to August 2016 and at Warp Drive Bio LLC, a biotechnology company, from June 2012 to November 2014. Earlier in his career, Dr. Simons was an Entrepreneurial Fellow at Flagship Pioneering, where he was a member of the founding team at Seres Therapeutics, Inc. Dr. Simons earned an A.B. magna cum laude in neuroscience and music from Harvard College, a Ph.D. in biomedical engineering from the Massachusetts Institute of Technology and an M.B.A. from Harvard Business School. - Emmanuel Simons于2016年3月共同创立了Akouos，自成立以来一直担任我们的总裁兼首席执行官，并担任我们的董事会成员。在创立Akouos之前，Simons博士于2014年11月至2016年8月在生物技术公司VoyagerTherapeutics，Inc.担任商业和企业发展领导职务，并于2012年6月至2014年11月在生物技术公司Warp Drive Bio LLC担任领导职务。在他的职业生涯早期，西蒙斯博士是旗舰创业公司（Flagship Pioneural）的一名企业家，也是赛里斯治疗公司创始团队的成员之一Simons博士在哈佛学院（Harvard College）以优异成绩获得神经科学和音乐学士学位，在麻省理工学院（Massachusetts Institute of Technology）获得生物医学工程博士学位，在哈佛商学院（Harvard Business School）获得工商管理硕士学位。
- Emmanuel Simons co-founded Akouos in March 2016 and has served as our president and chief executive officer and as a member of our board of directors since our inception. Prior to founding Akouos, Dr. Simons held leadership roles in business and corporate development at Voyager Therapeutics, Inc., a biotechnology company, from November 2014 to August 2016 and at Warp Drive Bio LLC, a biotechnology company, from June 2012 to November 2014. Earlier in his career, Dr. Simons was an Entrepreneurial Fellow at Flagship Pioneering, where he was a member of the founding team at Seres Therapeutics, Inc. Dr. Simons earned an A.B. magna cum laude in neuroscience and music from Harvard College, a Ph.D. in biomedical engineering from the Massachusetts Institute of Technology and an M.B.A. from Harvard Business School.
- Kush M. Parmar
-
暂无中文简介
Kush M. Parmar has served on our board of directors since October 2017. Dr. Parmar has been a Managing Partner and Member at 5AM Ventures, a venture capital firm, since January 2016. Previously, Dr. Parmar was a Partner from January 2014 to December 2016 and a Principal from January 2012 to December 2014 at 5AM Ventures. Dr. Parmar has served on the board of directors of Homology Medicines, Inc. since December 2015 and previously served on the board of directors of Arvinas, Inc. from July 2013 to November 2019 Audentes Therapeutics, Inc. from 2013 to November 2018 and scPharmaceuticals, Inc. from March 2014 to July 2018. Dr. Parmar holds a Ph.D. in experimental pathology from Harvard University, an M.D. from Harvard Medical School, and an A.B. in molecular biology and medieval studies from Princeton University. -
暂无中文简介
- Kush M. Parmar has served on our board of directors since October 2017. Dr. Parmar has been a Managing Partner and Member at 5AM Ventures, a venture capital firm, since January 2016. Previously, Dr. Parmar was a Partner from January 2014 to December 2016 and a Principal from January 2012 to December 2014 at 5AM Ventures. Dr. Parmar has served on the board of directors of Homology Medicines, Inc. since December 2015 and previously served on the board of directors of Arvinas, Inc. from July 2013 to November 2019 Audentes Therapeutics, Inc. from 2013 to November 2018 and scPharmaceuticals, Inc. from March 2014 to July 2018. Dr. Parmar holds a Ph.D. in experimental pathology from Harvard University, an M.D. from Harvard Medical School, and an A.B. in molecular biology and medieval studies from Princeton University.
- Chris Smith
-
Chris Smith自2019年9月以来一直担任我们的首席执行官，并担任我们的董事会成员。史密斯先生于2020年9月被任命为董事长。2015年至2018年，史密斯先生担任Cochlear Limited的首席执行官。加入Cochlear Limited公司之前，他曾担任Gyrus Group plc.、KCI、Prism and Cardinal Health公司的高级执行职务。Smith先生在德州农工大学（Texas A&M University）获得学士学位。
Chris Smith has been our Chief Executive Officer since September 2019 and he serves as a member of our board of directors. Mr. Smith was appointed Chairman in September 2020. From 2015 to 2018 Mr. Smith served as the Chief Executive Officer of Cochlear Limited. Prior to joining Cochlear Limited, he held senior executive roles at Gyrus Group Plc., KCI, Prism and Cardinal Health. Mr. Smith received a B.S. from Texas A&M University. - Chris Smith自2019年9月以来一直担任我们的首席执行官，并担任我们的董事会成员。史密斯先生于2020年9月被任命为董事长。2015年至2018年，史密斯先生担任Cochlear Limited的首席执行官。加入Cochlear Limited公司之前，他曾担任Gyrus Group plc.、KCI、Prism and Cardinal Health公司的高级执行职务。Smith先生在德州农工大学（Texas A&M University）获得学士学位。
- Chris Smith has been our Chief Executive Officer since September 2019 and he serves as a member of our board of directors. Mr. Smith was appointed Chairman in September 2020. From 2015 to 2018 Mr. Smith served as the Chief Executive Officer of Cochlear Limited. Prior to joining Cochlear Limited, he held senior executive roles at Gyrus Group Plc., KCI, Prism and Cardinal Health. Mr. Smith received a B.S. from Texas A&M University.
- Saira Ramasastry
-
Saira Ramasastry，2013年2月起担任董事。2013年之前，她是本公司的顾问。她从2009年起，担任Life Sciences Advisory, LLC的管理合伙人，这是一个生命科学行业的咨询公司。1999-2009，她是投资银行公司Merrill Lynch & Company的投资银行家。1997-1998，她是投资银行公司Wasserstein Perella & Co。并购部门的金融分析师。她目前是两家上市制药公司Sangamo Biosciences 和 Repros Therapeutics的董事，是Michael J. Fox Foundation for Parkinson’s Research行业咨询委员会成员，也是American Liver Foundation的董事。她以优等生的成绩获得了Stanford University的经济学士学位、管理学与工程硕士学位，并在 University of Cambridge获得管理研究的学术硕士学位。
Saira Ramasastry has served as a director since February 2013. Since 2009 she has served as Managing Partner of Life Sciences Advisory, LLC, a life science company advisory business. From 1999 to 2009 Ms. Ramasastry was an investment banker with Merrill Lynch & Company, Inc., an investment banking firm. Ms. Ramasastry serves on the Board of Directors of Sangamo Therapeutics, Inc., VIR Biotechnology, Inc., Innovate Biopharmaceuticals, Inc. and Glenmark Pharmaceuticals Ltd., each a publicly-held biopharmaceutical company, the Industry Advisory Board of the Michael J. Fox Foundation for Parkinson’s Research and the head of business and sustainability for the European Prevention of Alzheimer’s Dementia EPAD. She received her B.A. in Economics with Honors and Distinction and an M.S. in Management Science and Engineering from Stanford University, Phi Beta Kappa, as well as an M. Phil. in Management Studies from the University of Cambridge. - Saira Ramasastry，2013年2月起担任董事。2013年之前，她是本公司的顾问。她从2009年起，担任Life Sciences Advisory, LLC的管理合伙人，这是一个生命科学行业的咨询公司。1999-2009，她是投资银行公司Merrill Lynch & Company的投资银行家。1997-1998，她是投资银行公司Wasserstein Perella & Co。并购部门的金融分析师。她目前是两家上市制药公司Sangamo Biosciences 和 Repros Therapeutics的董事，是Michael J. Fox Foundation for Parkinson’s Research行业咨询委员会成员，也是American Liver Foundation的董事。她以优等生的成绩获得了Stanford University的经济学士学位、管理学与工程硕士学位，并在 University of Cambridge获得管理研究的学术硕士学位。
- Saira Ramasastry has served as a director since February 2013. Since 2009 she has served as Managing Partner of Life Sciences Advisory, LLC, a life science company advisory business. From 1999 to 2009 Ms. Ramasastry was an investment banker with Merrill Lynch & Company, Inc., an investment banking firm. Ms. Ramasastry serves on the Board of Directors of Sangamo Therapeutics, Inc., VIR Biotechnology, Inc., Innovate Biopharmaceuticals, Inc. and Glenmark Pharmaceuticals Ltd., each a publicly-held biopharmaceutical company, the Industry Advisory Board of the Michael J. Fox Foundation for Parkinson’s Research and the head of business and sustainability for the European Prevention of Alzheimer’s Dementia EPAD. She received her B.A. in Economics with Honors and Distinction and an M.S. in Management Science and Engineering from Stanford University, Phi Beta Kappa, as well as an M. Phil. in Management Studies from the University of Cambridge.
- Heather Preston
-
Heather Preston博士自2007年12月就是董事会成员。自2005年，Preston博士在TPG生物科技担任常务董事，该公司是一家生物科技风险投资公司。在加入TPG生物科技之前，Preston博士在摩根大通公司合作伙伴-LLC做了两年的医疗设备与生物科技风险投资的投资人，LLC是一家私人直接投资公司。在那之前，她是风险投资公司恩颐投资的入驻企业家。从1997年到2002年，Preston博士在位于纽约的麦肯锡担任药品和医疗产品咨询的负责人。Preston博士目前是许多私企董事会的常任董事。Preston博士取得了牛津大学医学博士学位以及伦敦大学生物化学理学士学位。
Heather Preston has served on our board of directors since February 2020. Dr. Preston is currently managing partner at Pivotal bioVentures, a venture capital firm, which she joined in July 2018. From May 2005 to July 2018 Dr. Preston was a firm partner and managing director of TPG Biotech, a venture capital firm. She currently serves on the boards of directors of Karuna Therapeutics since March 2019 Oxford Biomedica since March 2019 and Entasis Therapeutics Inc. since August 2017 and on the boards of a number of private companies. Dr. Preston previously served on the board of directors of Albireo Pharma, Inc. from November 2016 to June 2018 Alder Biopharmaceuticals from December 2007 to October 2019 and Otonomy, Inc. from August 2010 until February 2020. Prior to joining TPG Biotech, Dr. Preston served for two years as a medical device and biotechnology venture capital investor at JP Morgan Partners, LLC, a private equity firm. Prior to that, she was an entrepreneur-in-residence at New Enterprise Associates, a venture capital firm. Dr. Preston holds a B.Sc.Hons degree in biochemistry from the University of London and an M.B.B.Chir degree in medicine from the University of Oxford. After leaving Oxford, Dr. Preston completed a postdoctoral fellowship in molecular biology at the Dana Farber Cancer Institute, Harvard University. Dr. Preston completed her training in Internal Medicine at the Massachusetts General Hospital and then sub-specialized in Gastroenterology and Hepatology at U.C.S.F. During Dr. Preston's academic career, she was the recipient of a Fulbright Scholarship, a Fulbright Cancer Research Scholarship, a Harlech Scholarship, and a Science and Engineering Research Council Post-Doctoral Fellowship Award. - Heather Preston博士自2007年12月就是董事会成员。自2005年，Preston博士在TPG生物科技担任常务董事，该公司是一家生物科技风险投资公司。在加入TPG生物科技之前，Preston博士在摩根大通公司合作伙伴-LLC做了两年的医疗设备与生物科技风险投资的投资人，LLC是一家私人直接投资公司。在那之前，她是风险投资公司恩颐投资的入驻企业家。从1997年到2002年，Preston博士在位于纽约的麦肯锡担任药品和医疗产品咨询的负责人。Preston博士目前是许多私企董事会的常任董事。Preston博士取得了牛津大学医学博士学位以及伦敦大学生物化学理学士学位。
- Heather Preston has served on our board of directors since February 2020. Dr. Preston is currently managing partner at Pivotal bioVentures, a venture capital firm, which she joined in July 2018. From May 2005 to July 2018 Dr. Preston was a firm partner and managing director of TPG Biotech, a venture capital firm. She currently serves on the boards of directors of Karuna Therapeutics since March 2019 Oxford Biomedica since March 2019 and Entasis Therapeutics Inc. since August 2017 and on the boards of a number of private companies. Dr. Preston previously served on the board of directors of Albireo Pharma, Inc. from November 2016 to June 2018 Alder Biopharmaceuticals from December 2007 to October 2019 and Otonomy, Inc. from August 2010 until February 2020. Prior to joining TPG Biotech, Dr. Preston served for two years as a medical device and biotechnology venture capital investor at JP Morgan Partners, LLC, a private equity firm. Prior to that, she was an entrepreneur-in-residence at New Enterprise Associates, a venture capital firm. Dr. Preston holds a B.Sc.Hons degree in biochemistry from the University of London and an M.B.B.Chir degree in medicine from the University of Oxford. After leaving Oxford, Dr. Preston completed a postdoctoral fellowship in molecular biology at the Dana Farber Cancer Institute, Harvard University. Dr. Preston completed her training in Internal Medicine at the Massachusetts General Hospital and then sub-specialized in Gastroenterology and Hepatology at U.C.S.F. During Dr. Preston's academic career, she was the recipient of a Fulbright Scholarship, a Fulbright Cancer Research Scholarship, a Harlech Scholarship, and a Science and Engineering Research Council Post-Doctoral Fellowship Award.
- Edward T. Mathers
-
Edward T. Mathers，自2020年7月起担任Mbx Biosciences, Inc.董事会成员。自2008年8月以来，他一直担任风险投资公司New Enterprise Associates的合伙人。他目前担任Rhythm Pharmaceuticals, Inc.（纳斯达克代码：RYTM）， Inozyme Pharma, Inc.（纳斯达克代码：INZY）， Synlogic, Inc.（纳斯达克代码：SYBX）， Trevi Therapeutics, Inc.（纳斯达克代码：TRVI）， Reneo Pharmaceuticals, Inc.（纳斯达克代码：PHM）和Senti Biosciences, Inc.（纳斯达克代码：XBIO）以及一些私人生命科学公司的董事会成员。此前，Mathers先生于2019年11月至2022年9月担任Mirum Pharmaceuticals, Inc.（纳斯达克股票代码：MIRM）的董事会成员；2017年10月至2022年12月担任Akouos, Inc.（纳斯达克股票代码：AKUS，被Eli Lilly收购）的董事会成员；Ra Pharmaceuticals, Inc.（直到2020年4月被UCB S.A.收购）和Liquidia Corporation（纳斯达克股票代码：LQDA）的董事会成员，直到2019年5月。在加入New Enterprise Associates之前，他曾在MedImmune, Inc.（一家生物技术公司，于2007年被AstraZeneca PLC收购）担任各种企业发展职位，最终担任企业发展和风险执行副总裁。在此职位上，他还领导公司的风险投资子公司MedImmune Ventures, Inc.在此之前，他是吸气治疗系统公司（一家生物制药公司，现在被称为Nektar Therapeutics, Inc.）的营销和企业许可和收购副总裁。此前，他在Glaxo Wellcome, Inc.工作了15年，在那里他担任销售和营销职位，责任越来越大。他持有North Carolina State University的化学学士学位。
Edward T. Mathers has been a member of the Board since the closing of the Merger and previoly served as a member of Reneo's board of directors from December 2017 until the closing of the Merger. Mr. Mathers is Partner at New Enterprise Associates, Inc. (NEA), a private venture capital firm focing on technology and healthcare investments. Mr. Mathers serves on the board of directors of the following publicly traded life science companies: Trevi Therapeutics, Inc. (NASDAQ: TRVI) since July 2017, Rhythm Pharmaceuticals, Inc. (FSE: 1RV.F) since March 2010, Synlogic, Inc. (NASDAQ: SYBX) since October 2012, Senti Biosciences, Inc. (NASDAQ: SNTI) since July 2016 and MBX Biosciences, Inc. (NASDAQ: MBX) since July 2020. Mr. Mathers previoly served on the board of directors of the following publicly traded companies: Inozyme Pharma, Inc. (NASDAQ: INZY) from January 2017 to July 2025, ObsEva SA (OTC: OBSEF) from November 2015 to June 2023, Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) from November 2018 to September 2022, Akouos, Inc. from October 2017 to December 2022. From 2002 to 2008, Mr. Mathers served as Executive Vice President, Corporate Development and Venture at MedImmune, Inc., a biopharmaceutical company, and led its venture capital subsidiary, MedImmune Ventures, Inc. Before Joining MedImmune in 2002, Mr. Mathers was Vice President, Marketing and Corporate Licensing and Acquisitions at Inhale Therapeutic Systems, a biotechnology company. Previoly, Mr. Mathers spent 15 years a Glaxo llcome, Inc. (GlaxoSmithKline), where he held vario sales and marketing positions. Mr. Mathers received a B.S. in Chemistry from North Carolina State University. - Edward T. Mathers，自2020年7月起担任Mbx Biosciences, Inc.董事会成员。自2008年8月以来，他一直担任风险投资公司New Enterprise Associates的合伙人。他目前担任Rhythm Pharmaceuticals, Inc.（纳斯达克代码：RYTM）， Inozyme Pharma, Inc.（纳斯达克代码：INZY）， Synlogic, Inc.（纳斯达克代码：SYBX）， Trevi Therapeutics, Inc.（纳斯达克代码：TRVI）， Reneo Pharmaceuticals, Inc.（纳斯达克代码：PHM）和Senti Biosciences, Inc.（纳斯达克代码：XBIO）以及一些私人生命科学公司的董事会成员。此前，Mathers先生于2019年11月至2022年9月担任Mirum Pharmaceuticals, Inc.（纳斯达克股票代码：MIRM）的董事会成员；2017年10月至2022年12月担任Akouos, Inc.（纳斯达克股票代码：AKUS，被Eli Lilly收购）的董事会成员；Ra Pharmaceuticals, Inc.（直到2020年4月被UCB S.A.收购）和Liquidia Corporation（纳斯达克股票代码：LQDA）的董事会成员，直到2019年5月。在加入New Enterprise Associates之前，他曾在MedImmune, Inc.（一家生物技术公司，于2007年被AstraZeneca PLC收购）担任各种企业发展职位，最终担任企业发展和风险执行副总裁。在此职位上，他还领导公司的风险投资子公司MedImmune Ventures, Inc.在此之前，他是吸气治疗系统公司（一家生物制药公司，现在被称为Nektar Therapeutics, Inc.）的营销和企业许可和收购副总裁。此前，他在Glaxo Wellcome, Inc.工作了15年，在那里他担任销售和营销职位，责任越来越大。他持有North Carolina State University的化学学士学位。
- Edward T. Mathers has been a member of the Board since the closing of the Merger and previoly served as a member of Reneo's board of directors from December 2017 until the closing of the Merger. Mr. Mathers is Partner at New Enterprise Associates, Inc. (NEA), a private venture capital firm focing on technology and healthcare investments. Mr. Mathers serves on the board of directors of the following publicly traded life science companies: Trevi Therapeutics, Inc. (NASDAQ: TRVI) since July 2017, Rhythm Pharmaceuticals, Inc. (FSE: 1RV.F) since March 2010, Synlogic, Inc. (NASDAQ: SYBX) since October 2012, Senti Biosciences, Inc. (NASDAQ: SNTI) since July 2016 and MBX Biosciences, Inc. (NASDAQ: MBX) since July 2020. Mr. Mathers previoly served on the board of directors of the following publicly traded companies: Inozyme Pharma, Inc. (NASDAQ: INZY) from January 2017 to July 2025, ObsEva SA (OTC: OBSEF) from November 2015 to June 2023, Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) from November 2018 to September 2022, Akouos, Inc. from October 2017 to December 2022. From 2002 to 2008, Mr. Mathers served as Executive Vice President, Corporate Development and Venture at MedImmune, Inc., a biopharmaceutical company, and led its venture capital subsidiary, MedImmune Ventures, Inc. Before Joining MedImmune in 2002, Mr. Mathers was Vice President, Marketing and Corporate Licensing and Acquisitions at Inhale Therapeutic Systems, a biotechnology company. Previoly, Mr. Mathers spent 15 years a Glaxo llcome, Inc. (GlaxoSmithKline), where he held vario sales and marketing positions. Mr. Mathers received a B.S. in Chemistry from North Carolina State University.
高管简历
中英对照 | 中文 | 英文- Gregory Robinson
Gregory Robinson自2019年9月起担任我们的首席科学官。2016年8月至2019年7月，罗宾逊博士担任生物技术公司Nightstar Therapeutics Plc的首席科学官，该公司于2019年被BiogenInc.收购。2014年11月至2016年8月，Robinson博士担任Agilis Biotherapeutics LLC的首席科学官，该生物技术公司随后被PtcTherapeutics，Inc.收购从2007年到2014年，Robinson博士是Discovery Research Group的成员或领导，并担任Shire plc的科学许可高级总监，该公司是一家制药公司，被制药公司Takeda Pharmaceutical Company Limited收购，在那里他评估罕见疾病的机会。在加入Shire plc之前，Robinson博士从2003年到2007年领导了Eyetech Pharmaceuticals Inc.的生物学和药物发现小组。Robinson从1992年到2003年在Pharmacia Corporation和Hybridon，Inc.担任多个职位。Robinson博士拥有Macalester College的生物学学士学位和Boston University的生物化学博士学位。
Gregory Robinson has served as our chief scientific officer since September 2019. From August 2016 to July 2019 Dr. Robinson served as the chief scientific officer at Nightstar Therapeutics plc, a biotechnology company that was acquired by Biogen Inc. in 2019. From November 2014 to August 2016 Dr. Robinson served as chief scientific officer at Agilis Biotherapeutics LLC, a biotechnology company that was subsequently acquired by PTC Therapeutics, Inc. From 2007 to 2014 Dr. Robinson was a member of or led the discovery research group and was senior director of scientific licensing at Shire plc, a pharmaceutical company that was acquired by Takeda Pharmaceutical Company Limited, a pharmaceutical company, where he evaluated rare disease opportunities. Prior to joining Shire plc, Dr. Robinson led the biology and drug discovery group at Eyetech Pharmaceuticals Inc. from 2003 to 2007. From 1992 to 2003 Dr. Robinson held various positions at Pharmacia Corporation and Hybridon, Inc. Dr. Robinson holds a B.S. in Biology from Macalester College and a Ph.D. in Biochemistry from Boston University.- Gregory Robinson自2019年9月起担任我们的首席科学官。2016年8月至2019年7月，罗宾逊博士担任生物技术公司Nightstar Therapeutics Plc的首席科学官，该公司于2019年被BiogenInc.收购。2014年11月至2016年8月，Robinson博士担任Agilis Biotherapeutics LLC的首席科学官，该生物技术公司随后被PtcTherapeutics，Inc.收购从2007年到2014年，Robinson博士是Discovery Research Group的成员或领导，并担任Shire plc的科学许可高级总监，该公司是一家制药公司，被制药公司Takeda Pharmaceutical Company Limited收购，在那里他评估罕见疾病的机会。在加入Shire plc之前，Robinson博士从2003年到2007年领导了Eyetech Pharmaceuticals Inc.的生物学和药物发现小组。Robinson从1992年到2003年在Pharmacia Corporation和Hybridon，Inc.担任多个职位。Robinson博士拥有Macalester College的生物学学士学位和Boston University的生物化学博士学位。
- Gregory Robinson has served as our chief scientific officer since September 2019. From August 2016 to July 2019 Dr. Robinson served as the chief scientific officer at Nightstar Therapeutics plc, a biotechnology company that was acquired by Biogen Inc. in 2019. From November 2014 to August 2016 Dr. Robinson served as chief scientific officer at Agilis Biotherapeutics LLC, a biotechnology company that was subsequently acquired by PTC Therapeutics, Inc. From 2007 to 2014 Dr. Robinson was a member of or led the discovery research group and was senior director of scientific licensing at Shire plc, a pharmaceutical company that was acquired by Takeda Pharmaceutical Company Limited, a pharmaceutical company, where he evaluated rare disease opportunities. Prior to joining Shire plc, Dr. Robinson led the biology and drug discovery group at Eyetech Pharmaceuticals Inc. from 2003 to 2007. From 1992 to 2003 Dr. Robinson held various positions at Pharmacia Corporation and Hybridon, Inc. Dr. Robinson holds a B.S. in Biology from Macalester College and a Ph.D. in Biochemistry from Boston University.
- Emmanuel Simons
Emmanuel Simons于2016年3月共同创立了Akouos，自成立以来一直担任我们的总裁兼首席执行官，并担任我们的董事会成员。在创立Akouos之前，Simons博士于2014年11月至2016年8月在生物技术公司VoyagerTherapeutics，Inc.担任商业和企业发展领导职务，并于2012年6月至2014年11月在生物技术公司Warp Drive Bio LLC担任领导职务。在他的职业生涯早期，西蒙斯博士是旗舰创业公司（Flagship Pioneural）的一名企业家，也是赛里斯治疗公司创始团队的成员之一Simons博士在哈佛学院（Harvard College）以优异成绩获得神经科学和音乐学士学位，在麻省理工学院（Massachusetts Institute of Technology）获得生物医学工程博士学位，在哈佛商学院（Harvard Business School）获得工商管理硕士学位。
Emmanuel Simons co-founded Akouos in March 2016 and has served as our president and chief executive officer and as a member of our board of directors since our inception. Prior to founding Akouos, Dr. Simons held leadership roles in business and corporate development at Voyager Therapeutics, Inc., a biotechnology company, from November 2014 to August 2016 and at Warp Drive Bio LLC, a biotechnology company, from June 2012 to November 2014. Earlier in his career, Dr. Simons was an Entrepreneurial Fellow at Flagship Pioneering, where he was a member of the founding team at Seres Therapeutics, Inc. Dr. Simons earned an A.B. magna cum laude in neuroscience and music from Harvard College, a Ph.D. in biomedical engineering from the Massachusetts Institute of Technology and an M.B.A. from Harvard Business School.- Emmanuel Simons于2016年3月共同创立了Akouos，自成立以来一直担任我们的总裁兼首席执行官，并担任我们的董事会成员。在创立Akouos之前，Simons博士于2014年11月至2016年8月在生物技术公司VoyagerTherapeutics，Inc.担任商业和企业发展领导职务，并于2012年6月至2014年11月在生物技术公司Warp Drive Bio LLC担任领导职务。在他的职业生涯早期，西蒙斯博士是旗舰创业公司（Flagship Pioneural）的一名企业家，也是赛里斯治疗公司创始团队的成员之一Simons博士在哈佛学院（Harvard College）以优异成绩获得神经科学和音乐学士学位，在麻省理工学院（Massachusetts Institute of Technology）获得生物医学工程博士学位，在哈佛商学院（Harvard Business School）获得工商管理硕士学位。
- Emmanuel Simons co-founded Akouos in March 2016 and has served as our president and chief executive officer and as a member of our board of directors since our inception. Prior to founding Akouos, Dr. Simons held leadership roles in business and corporate development at Voyager Therapeutics, Inc., a biotechnology company, from November 2014 to August 2016 and at Warp Drive Bio LLC, a biotechnology company, from June 2012 to November 2014. Earlier in his career, Dr. Simons was an Entrepreneurial Fellow at Flagship Pioneering, where he was a member of the founding team at Seres Therapeutics, Inc. Dr. Simons earned an A.B. magna cum laude in neuroscience and music from Harvard College, a Ph.D. in biomedical engineering from the Massachusetts Institute of Technology and an M.B.A. from Harvard Business School.
- Michael McKenna
Michael McKenna于2016年3月共同创立了Akouos，自2018年6月起担任首席医疗官。McKenna博士是一位世界知名的神经内科医生，在转化内耳给药研究方面拥有专业知识。在加入Akouos之前，McKenna博士持有The Joseph B.Nadol，Jr.他于1989年加入Massachusetts Eye and Ear Infirmary（MEE）担任主席，自1996年起担任MEE耳鼻喉科主任和Harvard Medical School耳鼻喉科教授。McKenna博士持有南加州大学医学院（University of Southern California School of Medicine）的医学博士学位，在哈佛医学院（Harvard Medical School）完成耳鼻喉科住院医师资格，并在豪斯耳诊所（House Ear Clinic）完成神经外科和颅底外科的研究金。
Michael McKenna co-founded Akouos in March 2016 and has served as our chief medical officer since June 2018. Dr. McKenna is a world-renowned neurotologist with expertise in translational inner ear drug delivery research. Prior to joining Akouos, Dr. McKenna held the Joseph B. Nadol, Jr. Chair at the Massachusetts Eye and Ear Infirmary, or MEE, which he joined in 1989 and was the director of the Division of Otology and Neurotology at MEE and a professor of otolaryngology at Harvard Medical School since 1996. Dr. McKenna holds an M.D. from the University of Southern California School of Medicine, completed his otolaryngology residency at Harvard Medical School, and completed his fellowship in neurotology and base skull surgery at the House Ear Clinic.- Michael McKenna于2016年3月共同创立了Akouos，自2018年6月起担任首席医疗官。McKenna博士是一位世界知名的神经内科医生，在转化内耳给药研究方面拥有专业知识。在加入Akouos之前，McKenna博士持有The Joseph B.Nadol，Jr.他于1989年加入Massachusetts Eye and Ear Infirmary（MEE）担任主席，自1996年起担任MEE耳鼻喉科主任和Harvard Medical School耳鼻喉科教授。McKenna博士持有南加州大学医学院（University of Southern California School of Medicine）的医学博士学位，在哈佛医学院（Harvard Medical School）完成耳鼻喉科住院医师资格，并在豪斯耳诊所（House Ear Clinic）完成神经外科和颅底外科的研究金。
- Michael McKenna co-founded Akouos in March 2016 and has served as our chief medical officer since June 2018. Dr. McKenna is a world-renowned neurotologist with expertise in translational inner ear drug delivery research. Prior to joining Akouos, Dr. McKenna held the Joseph B. Nadol, Jr. Chair at the Massachusetts Eye and Ear Infirmary, or MEE, which he joined in 1989 and was the director of the Division of Otology and Neurotology at MEE and a professor of otolaryngology at Harvard Medical School since 1996. Dr. McKenna holds an M.D. from the University of Southern California School of Medicine, completed his otolaryngology residency at Harvard Medical School, and completed his fellowship in neurotology and base skull surgery at the House Ear Clinic.
- Rabia Gurses Ozden
Rabia Gurses Ozden自2019年10月起担任我们的首席开发官。从2019年1月到2019年8月，Ozden博士担任Nightstar Therapeutics Plc的首席医疗官，该公司是一家生物技术公司，于2019年被BiogenInc.收购。2018年3月至2019年5月，Ozden博士担任生物技术公司Clementia Pharmaceuticals，Inc.眼科临床研究与开发顾问主管。从2018年4月至2019年1月，Ozden博士担任生物技术公司Ionis Pharmaceuticals的眼科顾问，从2018年7月至2019年1月，Ozden博士担任生物技术公司ProQR Therapeutics和专业制药公司Nevakar，Inc.的眼科顾问。2015年7月至2018年3月，Ozden博士担任生物技术公司Applied Genetic Technologies Corporation临床研究与开发Vice President，2014年5月至2015年6月，Ozden博士担任制药公司GlaxoSmithKline plc Vice President兼临床眼科主管。在她的职业生涯早期，Ozden博士还在Quark Pharmaceuticals（一家制药公司）、Bausch&Lomb Pharmaceutical（Bausch Health CompaniesInc.的一个部门）和Carl Zeiss Meditec AG（一家技术公司和Carl Zeiss AG的子公司）担任临床开发和运营职务。Ozden博士在Hacettepe University School of Medicine获得医学博士学位，在安卡拉大学医学院（Ankara University School of Medicine）完成眼科住院医师学位，并在纽约眼耳医务室（New York Eye and Ear Infirmary）完成青光眼奖学金。
Rabia Gurses Ozden has served as our chief development officer since October 2019. From January 2019 to August 2019 Dr. Ozden served as the chief medical officer of Nightstar Therapeutics plc, a biotechnology company that was acquired by Biogen Inc. in 2019. From March 2018 to May 2019 Dr. Ozden served as consultant head of Ophthalmology Clinical Research and Development at Clementia Pharmaceuticals, Inc., a biotechnology company. From April 2018 to January 2019 Dr. Ozden served as an ophthalmology consultant for Ionis Pharmaceuticals, a biotechnology company, and from July 2018 to January 2019 Dr. Ozden served as an ophthalmology consultant for ProQR Therapeutics, a biotechnology company, and Nevakar, Inc., a specialty pharmaceutical company. From July 2015 to March 2018 Dr. Ozden served as vice president of clinical research and development at Applied Genetic Technologies Corporation, a biotechnology company, and from May 2014 to June 2015 Dr. Ozden served as vice president and head of clinical ophthalmology at GlaxoSmithKline plc, a pharmaceutical company. Earlier in her career, Dr. Ozden also held clinical development and operations roles at Quark Pharmaceuticals, a pharmaceutical company, Bausch & Lomb Pharmaceutical, a division of Bausch Health Companies Inc., and Carl Zeiss Meditec AG, a technology company and subsidiary of Carl Zeiss AG. Dr. Ozden earned her M.D. from Hacettepe University School of Medicine, completed an ophthalmology residency at Ankara University School of Medicine, and completed her fellowship in glaucoma at the New York Eye and Ear Infirmary.- Rabia Gurses Ozden自2019年10月起担任我们的首席开发官。从2019年1月到2019年8月，Ozden博士担任Nightstar Therapeutics Plc的首席医疗官，该公司是一家生物技术公司，于2019年被BiogenInc.收购。2018年3月至2019年5月，Ozden博士担任生物技术公司Clementia Pharmaceuticals，Inc.眼科临床研究与开发顾问主管。从2018年4月至2019年1月，Ozden博士担任生物技术公司Ionis Pharmaceuticals的眼科顾问，从2018年7月至2019年1月，Ozden博士担任生物技术公司ProQR Therapeutics和专业制药公司Nevakar，Inc.的眼科顾问。2015年7月至2018年3月，Ozden博士担任生物技术公司Applied Genetic Technologies Corporation临床研究与开发Vice President，2014年5月至2015年6月，Ozden博士担任制药公司GlaxoSmithKline plc Vice President兼临床眼科主管。在她的职业生涯早期，Ozden博士还在Quark Pharmaceuticals（一家制药公司）、Bausch&Lomb Pharmaceutical（Bausch Health CompaniesInc.的一个部门）和Carl Zeiss Meditec AG（一家技术公司和Carl Zeiss AG的子公司）担任临床开发和运营职务。Ozden博士在Hacettepe University School of Medicine获得医学博士学位，在安卡拉大学医学院（Ankara University School of Medicine）完成眼科住院医师学位，并在纽约眼耳医务室（New York Eye and Ear Infirmary）完成青光眼奖学金。
- Rabia Gurses Ozden has served as our chief development officer since October 2019. From January 2019 to August 2019 Dr. Ozden served as the chief medical officer of Nightstar Therapeutics plc, a biotechnology company that was acquired by Biogen Inc. in 2019. From March 2018 to May 2019 Dr. Ozden served as consultant head of Ophthalmology Clinical Research and Development at Clementia Pharmaceuticals, Inc., a biotechnology company. From April 2018 to January 2019 Dr. Ozden served as an ophthalmology consultant for Ionis Pharmaceuticals, a biotechnology company, and from July 2018 to January 2019 Dr. Ozden served as an ophthalmology consultant for ProQR Therapeutics, a biotechnology company, and Nevakar, Inc., a specialty pharmaceutical company. From July 2015 to March 2018 Dr. Ozden served as vice president of clinical research and development at Applied Genetic Technologies Corporation, a biotechnology company, and from May 2014 to June 2015 Dr. Ozden served as vice president and head of clinical ophthalmology at GlaxoSmithKline plc, a pharmaceutical company. Earlier in her career, Dr. Ozden also held clinical development and operations roles at Quark Pharmaceuticals, a pharmaceutical company, Bausch & Lomb Pharmaceutical, a division of Bausch Health Companies Inc., and Carl Zeiss Meditec AG, a technology company and subsidiary of Carl Zeiss AG. Dr. Ozden earned her M.D. from Hacettepe University School of Medicine, completed an ophthalmology residency at Ankara University School of Medicine, and completed her fellowship in glaucoma at the New York Eye and Ear Infirmary.